Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227196 · ClinicalTrials.gov registry record · Phase 1
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 546
- Enrollment target
NCT05227196: Completed Phase 1 study, sponsored by Novo Nordisk A/S.
NCT05227196 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 546 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (810% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05227196, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 546 participants
- Enrollment target
Study Summary
The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide. The study will consist of 3 groups and the treatment the participants will get is dependent on the group the participants will be enrolled in. The participants in group 1 will receive treatment for 22 weeks, group 2 for 21 weeks and group 3 for 20 weeks. The study will last up to 29 to 31 weeks for each participant. This includes a screening period (up to 4 weeks), a dose escalation period (up to 2 weeks), a treatment period (20 weeks) and a follow-up period (5 weeks after the last dose).
Primary Outcome
h∙nmol/L
Interventions
- DRUG Semaglutide D Dose 1
- DRUG Semaglutide D Dose 2
- DRUG Semaglutide D Dose 3
- DRUG Semaglutide Dose 4
- DRUG Semaglutide Dose 5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 546 participants |
| Start Date | 2022-02-04 |
| Est. Completion | 2023-08-08 |
| Phase | Phase 1 |
What the finished NCT05227196 record still lists
NCT05227196 is an interventional study that assigns participants to a tested intervention. The registered 546 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (810% higher).
The record links to 0 conditions, and to 5 interventions - of which Semaglutide D Dose 1 is the first listed.
NCT05227196 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05227196 about?
NCT05227196 is a clinical study titled "A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People". The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide. The study will consist of 3 groups and the treatment the participants will get is dependent on the group the participants will be enrolled in. ...
What is the current status of trial NCT05227196?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 546 participants. The study started on 2022-02-04. Estimated completion is 2023-08-08.
What interventions are being tested in trial NCT05227196?
The interventions under investigation include: Semaglutide D Dose 1 (DRUG), Semaglutide D Dose 2 (DRUG), Semaglutide D Dose 3 (DRUG), Semaglutide Dose 4 (DRUG), Semaglutide Dose 5 (DRUG).
Who is sponsoring clinical trial NCT05227196?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05227196's enrollment target sits among peer trials
546 35th of 2000 higher than 1,966 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
- NCT06850922 · 546 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI